Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemdisiran in atypical hemolytic uremic syndrome
NCT03999840Phase 2Withdrawn
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Jan 2021
- Primary completion
- Jan 2024
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of cemdisiran in atypical hemolytic uremic syndrome (aHUS), sponsored by Mario Negri Institute for Pharmacological Research. Planned start Jan 2021; status: withdrawn.
02
Drugs
cemdisiran
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NCT03999840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03999840.